Logo image of SAGE

SAGE THERAPEUTICS INC (SAGE) Stock Fundamental Analysis

NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock - Currency: USD

6.53  -0.08 (-1.21%)

After market: 6.66 +0.13 (+1.99%)

Fundamental Rating

3

Overall SAGE gets a fundamental rating of 3 out of 10. We evaluated SAGE against 561 industry peers in the Biotechnology industry. The financial health of SAGE is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SAGE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SAGE has reported negative net income.
SAGE had a negative operating cash flow in the past year.
SAGE had negative earnings in 4 of the past 5 years.
SAGE had negative operating cash flow in 4 of the past 5 years.
SAGE Yearly Net Income VS EBIT VS OCF VS FCFSAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

1.2 Ratios

With a Return On Assets value of -73.22%, SAGE is not doing good in the industry: 66.84% of the companies in the same industry are doing better.
SAGE has a Return On Equity of -86.15%. This is comparable to the rest of the industry: SAGE outperforms 49.55% of its industry peers.
Industry RankSector Rank
ROA -73.22%
ROE -86.15%
ROIC N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
SAGE Yearly ROA, ROE, ROICSAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

SAGE has a better Gross Margin (77.10%) than 83.42% of its industry peers.
In the last couple of years the Gross Margin of SAGE has declined.
The Profit Margin and Operating Margin are not available for SAGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
SAGE Yearly Profit, Operating, Gross MarginsSAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SAGE has more shares outstanding than it did 1 year ago.
SAGE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SAGE Yearly Shares OutstandingSAGE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SAGE Yearly Total Debt VS Total AssetsSAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -5.97, we must say that SAGE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.97, SAGE is not doing good in the industry: 63.81% of the companies in the same industry are doing better.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.97
ROIC/WACCN/A
WACC10.05%
SAGE Yearly LT Debt VS Equity VS FCFSAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

SAGE has a Current Ratio of 7.42. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.42, SAGE is in the better half of the industry, outperforming 70.23% of the companies in the same industry.
A Quick Ratio of 7.42 indicates that SAGE has no problem at all paying its short term obligations.
SAGE has a Quick ratio of 7.42. This is in the better half of the industry: SAGE outperforms 70.77% of its industry peers.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.42
SAGE Yearly Current Assets VS Current LiabilitesSAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

SAGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.90%, which is quite impressive.
Looking at the last year, SAGE shows a very negative growth in Revenue. The Revenue has decreased by -52.30% in the last year.
SAGE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.99% yearly.
EPS 1Y (TTM)39.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.89%
Revenue 1Y (TTM)-52.3%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%77.97%

3.2 Future

The Earnings Per Share is expected to grow by 14.05% on average over the next years. This is quite good.
The Revenue is expected to grow by 39.81% on average over the next years. This is a very strong growth
EPS Next Y44.51%
EPS Next 2Y24.95%
EPS Next 3Y19.47%
EPS Next 5Y14.05%
Revenue Next Year93.46%
Revenue Next 2Y65.25%
Revenue Next 3Y53.73%
Revenue Next 5Y39.81%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SAGE Yearly Revenue VS EstimatesSAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SAGE Yearly EPS VS EstimatesSAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAGE Price Earnings VS Forward Price EarningsSAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAGE Per share dataSAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as SAGE's earnings are expected to grow with 19.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.95%
EPS Next 3Y19.47%

More info and screens

0

5. Dividend

5.1 Amount

SAGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGE THERAPEUTICS INC

NASDAQ:SAGE (5/23/2025, 8:54:27 PM)

After market: 6.66 +0.13 (+1.99%)

6.53

-0.08 (-1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners79.77%
Inst Owner Change3.13%
Ins Owners0.34%
Ins Owner Change2.12%
Market Cap408.91M
Analysts67.2
Price Target8.21 (25.73%)
Short Float %8.32%
Short Ratio3.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.28%
Min EPS beat(2)-1.61%
Max EPS beat(2)2.18%
EPS beat(4)1
Avg EPS beat(4)-1.76%
Min EPS beat(4)-7.14%
Max EPS beat(4)2.18%
EPS beat(8)2
Avg EPS beat(8)-8.21%
EPS beat(12)4
Avg EPS beat(12)-5.53%
EPS beat(16)6
Avg EPS beat(16)-4.33%
Revenue beat(2)1
Avg Revenue beat(2)-2.63%
Min Revenue beat(2)-12.99%
Max Revenue beat(2)7.74%
Revenue beat(4)2
Avg Revenue beat(4)6.19%
Min Revenue beat(4)-12.99%
Max Revenue beat(4)34.14%
Revenue beat(8)4
Avg Revenue beat(8)3.04%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)6
Avg Revenue beat(16)-5.56%
PT rev (1m)0.74%
PT rev (3m)0.73%
EPS NQ rev (1m)1.94%
EPS NQ rev (3m)-0.47%
EPS NY rev (1m)-2.1%
EPS NY rev (3m)-1.9%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)-1.33%
Revenue NY rev (1m)1.67%
Revenue NY rev (3m)-8.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.91
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-5.8
EYN/A
EPS(NY)-2.89
Fwd EYN/A
FCF(TTM)-4.27
FCFYN/A
OCF(TTM)-4.27
OCFYN/A
SpS0.66
BVpS7.43
TBVpS7.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.22%
ROE -86.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.1%
FCFM N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.42
Altman-Z -5.97
F-Score2
WACC10.05%
ROIC/WACCN/A
Cap/Depr(3y)40.51%
Cap/Depr(5y)28.52%
Cap/Sales(3y)4.11%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.89%
EPS Next Y44.51%
EPS Next 2Y24.95%
EPS Next 3Y19.47%
EPS Next 5Y14.05%
Revenue 1Y (TTM)-52.3%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%77.97%
Revenue Next Year93.46%
Revenue Next 2Y65.25%
Revenue Next 3Y53.73%
Revenue Next 5Y39.81%
EBIT growth 1Y24.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.13%
EBIT Next 3Y21.59%
EBIT Next 5Y14.08%
FCF growth 1Y50.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.57%
OCF growth 3YN/A
OCF growth 5YN/A